The effects of systemic immunomodulatory treatments on <scp>COVID</scp>‐19 outcomes in patients with atopic dermatitis: Results from the global <scp>SECURE‐AD</scp> registry

Abstract

Overall, the risk of COVID-19 complications appears low in patients with AD, even when treated with systemic immunomodulatory agents. Dupilumab monotherapy was associated with lower hospitalization than other therapies. Combination systemic treatment, particularly combinations including systemic corticosteroids, was associated with the highest risk of severe COVID-19.